P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations

S Rastogi, S Bosnic-Antievich, I Pavord, N Roche, D Halpin, L Bjermer, O S Usmani, G Brusselle, S Wan Yau Ming, S Halim, G Gopalan, D Price

Research output: Contribution to journalAbstract

Abstract

Introduction and Objectives Blood eosinophil counts (BltextendashEos) and fractional exhaled nitric oxide concentrations (FeNO) are established biomarkers in asthma. While patients with raised BltextendashEos are at increased risk of asthma exacerbations, it is unclear whether raised FeNO is associated with further increased risk. We sought to determine if raised BltextendashEos combined with raised FeNO was associated with increased frequency of asthma exacerbations.Methods This was a cross-sectional study of data from the Optimum Patient Care Research Database. Patients included were aged 18textendash80 years with >=1 year of continuous electronic health records prior to their most recent FeNO readings, had evidence of asthma, had received >=1 inhaled corticosteroid prescription, and had BltextendashEos recorded within 5 years of FeNO reading. Cohorts were determined by: BltextendashEos raised (>=0.25texttimes109/L, a cutoff representing the sample mean) and not raised (lt;0.25texttimes109/L) and, FeNO raised (>=35 ppb) and not raised (lt;35 ppb). Patients were directly matched on age, sex, and smoking status. Patients with (i) raised BltextendashEos and not raised FeNO, (ii) raised FeNO and not raised BltextendashEos, or (iii) both biomarkers raised were compared with reference patients (neither biomarker raised). Comparison of exacerbations (evidenced by acute oral corticosteroid prescription or unplanned asthma-related hospital attendance) was conducted using conditional Poisson regression.Results The unmatched study population consisted of 610 patients (mean age 52, 38% male, 46% non-smokers). With 1:1 matching, both the (i) raised BltextendashEos and not raised FeNO cohort (n=186) and the (ii) raised FeNO and not raised BltextendashEos cohort (n=98) demonstrated a trend toward greater exacerbation rates (unadjusted rate ratio: 1.41 [95% CI 0.91, 2.19] and 1.35 [95% CI 0.99 1.84], respectively) vs. reference group. Importantly, however, when both biomarkers were raised (n=53), a significantly greater exacerbation rate was observed (1.72 [95% CI 1.00, 2.93]).Conclusion The combination of raised FeNO and raised BltextendashEos was associated with a greater exacerbation rate compared with neither biomarker raised. FeNO and BltextendashEos are simple primary care measurements that could reliably predict exacerbation risk for asthma patients. This should be confirmed prospectively in larger populations.Please refer to page A258 for declarations of interest in relation to abstract P198.
Original languageEnglish
Pages (from-to)A190
JournalThorax
Volume72
Issue numberSuppl 3
Early online date15 Nov 2017
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Eosinophils
Nitric Oxide
Asthma
Biomarkers
Prescriptions
Reading
Adrenal Cortex Hormones
Electronic Health Records
Population
Primary Health Care
Patient Care
Cross-Sectional Studies
Smoking
Databases

Cite this

Rastogi, S., Bosnic-Antievich, S., Pavord, I., Roche, N., Halpin, D., Bjermer, L., ... Price, D. (2017). P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations. Thorax, 72(Suppl 3), A190. https://doi.org/10.1136/thoraxjnl-2017-210983.340

P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations. / Rastogi, S; Bosnic-Antievich, S; Pavord, I; Roche, N; Halpin, D; Bjermer, L; Usmani, O S; Brusselle, G; Ming, S Wan Yau; Halim, S; Gopalan, G; Price, D.

In: Thorax, Vol. 72, No. Suppl 3, 01.12.2017, p. A190.

Research output: Contribution to journalAbstract

Rastogi, S, Bosnic-Antievich, S, Pavord, I, Roche, N, Halpin, D, Bjermer, L, Usmani, OS, Brusselle, G, Ming, SWY, Halim, S, Gopalan, G & Price, D 2017, 'P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations', Thorax, vol. 72, no. Suppl 3, pp. A190. https://doi.org/10.1136/thoraxjnl-2017-210983.340
Rastogi S, Bosnic-Antievich S, Pavord I, Roche N, Halpin D, Bjermer L et al. P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations. Thorax. 2017 Dec 1;72(Suppl 3):A190. https://doi.org/10.1136/thoraxjnl-2017-210983.340
Rastogi, S ; Bosnic-Antievich, S ; Pavord, I ; Roche, N ; Halpin, D ; Bjermer, L ; Usmani, O S ; Brusselle, G ; Ming, S Wan Yau ; Halim, S ; Gopalan, G ; Price, D. / P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations. In: Thorax. 2017 ; Vol. 72, No. Suppl 3. pp. A190.
@article{679daef0376947188260316bf9b16382,
title = "P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations",
abstract = "Introduction and Objectives Blood eosinophil counts (BltextendashEos) and fractional exhaled nitric oxide concentrations (FeNO) are established biomarkers in asthma. While patients with raised BltextendashEos are at increased risk of asthma exacerbations, it is unclear whether raised FeNO is associated with further increased risk. We sought to determine if raised BltextendashEos combined with raised FeNO was associated with increased frequency of asthma exacerbations.Methods This was a cross-sectional study of data from the Optimum Patient Care Research Database. Patients included were aged 18textendash80 years with >=1 year of continuous electronic health records prior to their most recent FeNO readings, had evidence of asthma, had received >=1 inhaled corticosteroid prescription, and had BltextendashEos recorded within 5 years of FeNO reading. Cohorts were determined by: BltextendashEos raised (>=0.25texttimes109/L, a cutoff representing the sample mean) and not raised (lt;0.25texttimes109/L) and, FeNO raised (>=35 ppb) and not raised (lt;35 ppb). Patients were directly matched on age, sex, and smoking status. Patients with (i) raised BltextendashEos and not raised FeNO, (ii) raised FeNO and not raised BltextendashEos, or (iii) both biomarkers raised were compared with reference patients (neither biomarker raised). Comparison of exacerbations (evidenced by acute oral corticosteroid prescription or unplanned asthma-related hospital attendance) was conducted using conditional Poisson regression.Results The unmatched study population consisted of 610 patients (mean age 52, 38{\%} male, 46{\%} non-smokers). With 1:1 matching, both the (i) raised BltextendashEos and not raised FeNO cohort (n=186) and the (ii) raised FeNO and not raised BltextendashEos cohort (n=98) demonstrated a trend toward greater exacerbation rates (unadjusted rate ratio: 1.41 [95{\%} CI 0.91, 2.19] and 1.35 [95{\%} CI 0.99 1.84], respectively) vs. reference group. Importantly, however, when both biomarkers were raised (n=53), a significantly greater exacerbation rate was observed (1.72 [95{\%} CI 1.00, 2.93]).Conclusion The combination of raised FeNO and raised BltextendashEos was associated with a greater exacerbation rate compared with neither biomarker raised. FeNO and BltextendashEos are simple primary care measurements that could reliably predict exacerbation risk for asthma patients. This should be confirmed prospectively in larger populations.Please refer to page A258 for declarations of interest in relation to abstract P198.",
author = "S Rastogi and S Bosnic-Antievich and I Pavord and N Roche and D Halpin and L Bjermer and Usmani, {O S} and G Brusselle and Ming, {S Wan Yau} and S Halim and G Gopalan and D Price",
year = "2017",
month = "12",
day = "1",
doi = "10.1136/thoraxjnl-2017-210983.340",
language = "English",
volume = "72",
pages = "A190",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group Ltd",
number = "Suppl 3",

}

TY - JOUR

T1 - P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations

AU - Rastogi, S

AU - Bosnic-Antievich, S

AU - Pavord, I

AU - Roche, N

AU - Halpin, D

AU - Bjermer, L

AU - Usmani, O S

AU - Brusselle, G

AU - Ming, S Wan Yau

AU - Halim, S

AU - Gopalan, G

AU - Price, D

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Introduction and Objectives Blood eosinophil counts (BltextendashEos) and fractional exhaled nitric oxide concentrations (FeNO) are established biomarkers in asthma. While patients with raised BltextendashEos are at increased risk of asthma exacerbations, it is unclear whether raised FeNO is associated with further increased risk. We sought to determine if raised BltextendashEos combined with raised FeNO was associated with increased frequency of asthma exacerbations.Methods This was a cross-sectional study of data from the Optimum Patient Care Research Database. Patients included were aged 18textendash80 years with >=1 year of continuous electronic health records prior to their most recent FeNO readings, had evidence of asthma, had received >=1 inhaled corticosteroid prescription, and had BltextendashEos recorded within 5 years of FeNO reading. Cohorts were determined by: BltextendashEos raised (>=0.25texttimes109/L, a cutoff representing the sample mean) and not raised (lt;0.25texttimes109/L) and, FeNO raised (>=35 ppb) and not raised (lt;35 ppb). Patients were directly matched on age, sex, and smoking status. Patients with (i) raised BltextendashEos and not raised FeNO, (ii) raised FeNO and not raised BltextendashEos, or (iii) both biomarkers raised were compared with reference patients (neither biomarker raised). Comparison of exacerbations (evidenced by acute oral corticosteroid prescription or unplanned asthma-related hospital attendance) was conducted using conditional Poisson regression.Results The unmatched study population consisted of 610 patients (mean age 52, 38% male, 46% non-smokers). With 1:1 matching, both the (i) raised BltextendashEos and not raised FeNO cohort (n=186) and the (ii) raised FeNO and not raised BltextendashEos cohort (n=98) demonstrated a trend toward greater exacerbation rates (unadjusted rate ratio: 1.41 [95% CI 0.91, 2.19] and 1.35 [95% CI 0.99 1.84], respectively) vs. reference group. Importantly, however, when both biomarkers were raised (n=53), a significantly greater exacerbation rate was observed (1.72 [95% CI 1.00, 2.93]).Conclusion The combination of raised FeNO and raised BltextendashEos was associated with a greater exacerbation rate compared with neither biomarker raised. FeNO and BltextendashEos are simple primary care measurements that could reliably predict exacerbation risk for asthma patients. This should be confirmed prospectively in larger populations.Please refer to page A258 for declarations of interest in relation to abstract P198.

AB - Introduction and Objectives Blood eosinophil counts (BltextendashEos) and fractional exhaled nitric oxide concentrations (FeNO) are established biomarkers in asthma. While patients with raised BltextendashEos are at increased risk of asthma exacerbations, it is unclear whether raised FeNO is associated with further increased risk. We sought to determine if raised BltextendashEos combined with raised FeNO was associated with increased frequency of asthma exacerbations.Methods This was a cross-sectional study of data from the Optimum Patient Care Research Database. Patients included were aged 18textendash80 years with >=1 year of continuous electronic health records prior to their most recent FeNO readings, had evidence of asthma, had received >=1 inhaled corticosteroid prescription, and had BltextendashEos recorded within 5 years of FeNO reading. Cohorts were determined by: BltextendashEos raised (>=0.25texttimes109/L, a cutoff representing the sample mean) and not raised (lt;0.25texttimes109/L) and, FeNO raised (>=35 ppb) and not raised (lt;35 ppb). Patients were directly matched on age, sex, and smoking status. Patients with (i) raised BltextendashEos and not raised FeNO, (ii) raised FeNO and not raised BltextendashEos, or (iii) both biomarkers raised were compared with reference patients (neither biomarker raised). Comparison of exacerbations (evidenced by acute oral corticosteroid prescription or unplanned asthma-related hospital attendance) was conducted using conditional Poisson regression.Results The unmatched study population consisted of 610 patients (mean age 52, 38% male, 46% non-smokers). With 1:1 matching, both the (i) raised BltextendashEos and not raised FeNO cohort (n=186) and the (ii) raised FeNO and not raised BltextendashEos cohort (n=98) demonstrated a trend toward greater exacerbation rates (unadjusted rate ratio: 1.41 [95% CI 0.91, 2.19] and 1.35 [95% CI 0.99 1.84], respectively) vs. reference group. Importantly, however, when both biomarkers were raised (n=53), a significantly greater exacerbation rate was observed (1.72 [95% CI 1.00, 2.93]).Conclusion The combination of raised FeNO and raised BltextendashEos was associated with a greater exacerbation rate compared with neither biomarker raised. FeNO and BltextendashEos are simple primary care measurements that could reliably predict exacerbation risk for asthma patients. This should be confirmed prospectively in larger populations.Please refer to page A258 for declarations of interest in relation to abstract P198.

U2 - 10.1136/thoraxjnl-2017-210983.340

DO - 10.1136/thoraxjnl-2017-210983.340

M3 - Abstract

VL - 72

SP - A190

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - Suppl 3

ER -